You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Suppliers and packagers for generic pharmaceutical drug: DEXTROMETHORPHAN POLISTIREX


✉ Email this page to a colleague

« Back to Dashboard


DEXTROMETHORPHAN POLISTIREX

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Rb Hlth DELSYM dextromethorphan polistirex SUSPENSION, EXTENDED RELEASE;ORAL 018658 NDA ATLANTIC BIOLOGICALS CORP. 17856-0172-3 1 BOX, UNIT-DOSE in 1 CUP, UNIT-DOSE (17856-0172-3) / 72 CUP, UNIT-DOSE in 1 BOX, UNIT-DOSE (17856-0172-2) / 5 mL in 1 CUP, UNIT-DOSE 2018-12-17
Rb Hlth DELSYM dextromethorphan polistirex SUSPENSION, EXTENDED RELEASE;ORAL 018658 NDA ATLANTIC BIOLOGICALS CORP. 17856-0172-4 1 BOX, UNIT-DOSE in 1 CUP, UNIT-DOSE (17856-0172-4) / 72 CUP, UNIT-DOSE in 1 BOX, UNIT-DOSE (17856-0172-1) / 10 mL in 1 CUP, UNIT-DOSE 2018-12-17
Rb Hlth DELSYM dextromethorphan polistirex SUSPENSION, EXTENDED RELEASE;ORAL 018658 NDA A-S Medication Solutions 50090-0224-0 1 BOTTLE in 1 CARTON (50090-0224-0) / 89 mL in 1 BOTTLE 2010-05-04
Rb Hlth DELSYM dextromethorphan polistirex SUSPENSION, EXTENDED RELEASE;ORAL 018658 NDA RB Health (US) LLC 63824-171-22 2 CARTON in 1 CELLO PACK (63824-171-22) / 1 BOTTLE in 1 CARTON / 148 mL in 1 BOTTLE 2010-05-04
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Dextromethorphan Polistirex

Last updated: August 1, 2025

Introduction

Dextromethorphan Polistirex is a sustained-release formulation of dextromethorphan, primarily used as an antitussive agent in over-the-counter (OTC) cold and cough medications. Its unique delivery system enables prolonged action, improving therapeutic efficacy by maintaining consistent plasma drug levels. The pharmaceutical supply chain for dextromethorphan polistirex is global, encompassing raw material producers, formulation developers, and bulk suppliers. Understanding these suppliers’ landscape is vital for pharmaceutical companies, healthcare providers, and regulators aiming to ensure drug quality, supply continuity, and regulatory compliance.

Overview of Dextromethorphan Polistirex and Market Dynamics

Dextromethorphan (DXM) is a non-opioid cough suppressant, valued for its safety profile when used appropriately. Polistirex forms create a complex with dextromethorphan embedded in a polymer matrix that allows slow release over hours[1]. The demand for dextromethorphan polistirex stems from its use in popular OTC products, including Robitussin DM and Delsym. The global market is driven by increased consumer healthcare spending, expanding OTC markets, and respiratory illness prevalence. Supply chain vulnerabilities, regulatory factors, and raw material sourcing critically influence availability.

Key Raw Material Suppliers

1. Dextromethorphan Hydrobromide Raw Material Suppliers

Dextromethorphan hydrobromide, the active ingredient, is synthesized via chemical processes involving key intermediates. Major raw material suppliers include:

  • Sigma-Aldrich (Merck Millipore)
    As a prominent global supplier, Sigma-Aldrich offers pharmaceutical-grade dextromethorphan hydrobromide, adhering to Good Manufacturing Practices (GMP). Their extensive distribution network ensures supply reliability for formulators.

  • Thermo Fisher Scientific
    Provides high-purity dextromethorphan hydrobromide, often used in clinical and manufacturing settings. Their global footprint supports timely delivery to major markets.

  • LGM Pharma
    Specializes in active pharmaceutical ingredients (APIs) with a broad portfolio, including dextromethorphan hydrobromide. They provide custom synthesis options and certification supporting regulatory submissions[2].

2. Polymer Carriers and Formulation Excipients Suppliers

The polistirex matrix is typically composed of styrene-based polymers and other excipients:

  • Styrene-Butadiene-Styrene (SBS) Polymers Suppliers
    Companies like Kuraray and Styrolution supply high-quality styrene-based polymers used in sustained-release formulations. Their polymers undergo rigorous characterization to ensure compatibility and stability.

  • Excipients and Additives Manufacturers
    Suppliers such as Ashland and BASF provide pharmaceutical-grade excipients, stabilizers, and surfactants crucial for the polistirex matrix formation.

Formulation and Contract Manufacturing Organizations (CMOs)

Many pharmaceutical firms outsource formulation and manufacturing to CMOs that specialize in sustained-release systems:

  • Famar (Greece)
    Offers comprehensive APIs sourcing, formulation development, and finished product manufacturing, including dextromethorphan polistirex.

  • Kindeva Drug Delivery
    A leading CMO with expertise in extended-release formulations, offering custom manufacturing for dextromethorphan polistirex.

  • Recipharm and Baxter
    Both provide scalable manufacturing solutions, ensuring supply chain resilience for OTC products containing dextromethorphan polistirex.

Regional Suppliers and Emerging Markets

Emerging markets provide alternative sourcing options:

  • China-based Suppliers
    Many Chinese chemical synthesizers and formulation firms offer dextromethorphan hydrobromide and related sustained-release systems at competitive costs. Companies like Hubei Mingxing Pharmaceutical and Shandong Yulong Pharmaceutical produce API intermediates and finished formulations.

  • India-based Manufacturers
    Firms like Aarti Industries and Divi's Laboratories supply APIs and excipients, catering to domestic and export markets, often with robust regulatory registrations in India and emerging markets.

Regulatory and Quality Considerations

Selection of suppliers involves rigorous evaluation of quality certifications, including:

  • GMP compliance (e.g., US FDA, EMA certifications)
  • ISO 9001 certifications
  • Certificate of Analysis (CoA) for each batch
  • Evidence of regulatory filings and approvals in target markets

Due to the potential misuse of dextromethorphan (as a psychoactive substance), suppliers must also comply with regulatory controls and reporting obligations in jurisdictions such as the US (DEA Controlled Substances Act) and the European Union.

Risks and Supply Chain Resilience

Supply disruptions can occur due to geopolitical tensions, regulatory changes, or raw material shortages. Companies mitigating these risks often diversify their supplier base across regions and maintain strategic stockpiles. Moreover, establishing long-term partnerships and tight supply agreements aids in securing consistent quality and supply.

Conclusion

The supplier landscape for dextromethorphan polistirex is multifaceted, comprising global and regional entities specializing in raw materials, excipients, and formulation services. Leading international suppliers like Sigma-Aldrich and Thermo Fisher, combined with regional manufacturers in China and India, form the backbone of this supply chain. Ensuring regulatory compliance and quality standards are paramount in maintaining a reliable supply of this widely used antitussive agent.


Key Takeaways

  • Dextromethorphan hydrobromide suppliers include global players like Sigma-Aldrich and Thermo Fisher, offering high-quality APIs essential for formulation.

  • Polymer and excipient suppliers such as Kuraray and BASF are crucial in creating the sustained-release properties characteristic of dextromethorphan polistirex.

  • Contract manufacturing organizations (CMOs) play a key role in formulation development and production scalability, supporting supply chain robustness.

  • Regional suppliers in China and India provide alternative sources at competitive costs, but strict quality and regulatory compliance are vital.

  • Managing supply risks involves diversification, quality assurance, regulatory compliance, and proactive inventory management.


FAQs

1. What are the primary raw materials used in manufacturing dextromethorphan polistirex?
The key raw material is dextromethorphan hydrobromide, synthesized via chemical processes involving intermediates like 3-methoxyphenylacetone. The polistirex matrix incorporates styrene-based polymers to achieve sustained release.

2. How do global supply chain disruptions affect the availability of dextromethorphan polistirex?
Disruptions can lead to delays, shortages, or quality issues. Dependence on regional suppliers, geopolitical tensions, and raw material shortages compound risks, emphasizing the importance of diversified sourcing and strategic stockpiles.

3. What quality certifications should suppliers possess?
Suppliers should have GMP compliance, ISO 9001 certification, and detailed Certificates of Analysis. Regulatory approvals or audits by agencies like the FDA or EMA further ensure manufacturing standards.

4. Can regional suppliers in China and India meet global quality standards?
Yes, many regional suppliers adhere to international GMP standards, and gaining regulatory approval requires rigorous documentation and compliance verification. Due diligence is essential before qualification.

5. Are there ethical or regulatory considerations related to sourcing dextromethorphan?
Yes, dextromethorphan’s potential misuse necessitates strict regulatory adherence, including reporting and tracking by suppliers, especially in jurisdictions that classify it as a controlled substance.


References

[1] Pharmacology and Clinical Use of Dextromethorphan, American Journal of Therapeutics, 2022.
[2] LGM Pharma Product Portfolio, LGM Pharma Official Website, 2023.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.